THERAMETRICS
LIVE

Serial Number

79143473

Owner

THERAMetrics holding AG

Attorney

Steven A. Abreu

Filing Date

Nov 22, 2013

Add to watchlist:

No watchlists yet
View on USPTO

THERAMETRICS Trademark

Serial Number: 79143473 • Registration: 4654777

THERAMETRICS is a trademark filed by THERAMetrics holding AG on November 22, 2013. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

THERAMetrics holding AG (2 trademarks)

Das Kloster

Entity Type: 99

Trademark Details

Filing Date

November 22, 2013

Registration Date

December 16, 2014

Published for Opposition

September 30, 2014

Cancellation Date

November 21, 2023

Goods & Services

Pharmaceutical preparations for the treatment of cardiovascular and respiratory diseases, pulmonary fibrosis, sarcoidosis, lung disease, viral diseases, and infectious diseases; chemical preparations for sanitary purposes for medicine; pharmaceutical products for the treatment of idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, scleroderma, lupus erythematosus associated pulmonary hypertension, congenital systemic-to-pulmonary shunts associated pulmonary hypertension, portal hypertension associated pulmonary hypertension, HIV infection associated pulmonary hypertension, drugs and toxins associated pulmonary hypertension, glycogen storage disease associated pulmonary hypertension, Gaucher disease associated pulmonary hypertension, hereditary hemorrhagic telangiectasia associated pulmonary hypertension, hemoglobinopathies associated pulmonary hypertension, myeloproliferative disorders associated pulmonary hypertension, pulmonary veno-occlusive disease associated pulmonary hypertension, pulmonary capillary hemangiomatosis associated pulmonary hypertension, persistent pulmonary hypertension of the newborn, left-sided atrial or ventricular heart disease associated pulmonary hypertension, left-sided valvular heart disease associated pulmonary hypertension, pulmonary hypertension associated with chronic obstructive pulmonary disease, pulmonary hypertension associated with interstitial lung diseases, pulmonary hypertension associated with sleep disordered-breathing, pulmonary hypertension associated with alveolar hypoventilation disorders, pulmonary hypertension associated with chronic exposure to high altitude, pulmonary hypertension associated with developmental abnormalities, pulmonary hypertension due to chronic thrombotic and embolic diseases, pulmonary embolism due to tumor, parasites, foreign material, pulmonary hypertension associated with in situ thrombosis, pulmonary hypertension associated with sarcoidosis, pulmonary hypertension associated with histiocytosis X, pulmonary hypertension associated with lymphangiomatosis, pulmonary hypertension associated with sickle-cell disease, Eisenmenger syndrome, chronic fatigue syndrome, bronchial asthma, rheumatoid arthritis, lupus, Goodpasture's syndrome, Wegener's granulomatosis, type 1 diabetes mellitus, Hashimoto's thyroiditis, Grave's disease, multiple sclerosis, Guillain-Barre syndrome, Addison's disease, acute disseminated encephalomyelitis, antiphospholipid antibody syndrome, aplastic anemia, myasthenia gravis, opsoclonus myoclonus syndrome, optic neuritis, Ord's thyroiditis, acute respiratory distress syndrome, acute lung injury, Hamman-Rich syndrome, idiopathic pulmonary fibrosis, bronchiolitis obliterans, hypersensitivity pneumonitis, lymphangiomyomatosis (LAM), usual interstitial pneumonia (UIP), Von Gierke syndrome, Osler-Weber-Rendu-Syndrome, small cell lung carcinoma, cystic fibrosis, tuberculosis, Hepatitis B virus infections, psoriasis, allergic dermatitis, scar keloids, pyogenic granulomas, blistering disease, Kaposi sarcoma in AIDS patients, systemic sclerosis, persistent hyperplastic vitreous syndrome, diabetic retinopathy, retinopathy of prematurity, choroidal neovascularization, inflammatory bowel disease, periodontal disease, ascites, peritoneal adhesions, endometriosis, uterine bleeding, ovarian cysts, ovarian hyperstimulation, osteomyelitis, osteophyte formation, HIV-induced bone marrow angiogenesis, early diabetic nephropathy, cancer and malignancies and their metastases in numerous organs, hemangiomas, vasculitis, Sjögren's disease, DiGeorge syndrome, hereditary haemorrhagic telangiectasia, cavernous hemangioma, cutaneous hemangioma, lymphatic malformations, transplant arteriopathy, vascular anastomoses, adipose tissue in obesity, chronic allograft rejections; chemical preparations intended for healing, health care or medical and veterinary purposes, namely, chemical preparations for treating inflammatory, cardiovascular and respiratory diseases, pulmonary fibrosis, sarcoidosis, lung disease, viral diseases, and infectious diseases; chemical reagents for medical or veterinary purposes; diagnostic preparations for medical purposes; radiological contrast substances for medical purposes; detergents for medical purposes; medicated mouth care and treatment preparations; medicated skin care preparations

Scientific research to order; conducting of research and development in the medical, pharmaceutical, pharmacological, biochemical and/or medical technology fields for others; conducting to order clinical studies and tests, namely, conducting clinical trials for others; assessment to order of scientific projects, namely, conducting scientific feasibility studies; scientific research consulting in the nature of evaluation to order of clinical studies and experiments; providing technical advice relating to operation of computers; providing scientific cooperations in the nature of providing scientific information in the field of pharmaceutical research; conducting scientific research projects in the medical, pharmaceutical, pharmacological, biochemical, and/or medical technology fields for others; scientific analysis laboratories

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Jun 16, 2024 DENA
DEATH OF INTERNATIONAL REGISTRATION
Jun 16, 2024 DETH
TOTAL INVALIDATION PROCESSED BY THE IB
Aug 8, 2022 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Jul 7, 2022 INTS
INVALIDATION PROCESSED
Jul 7, 2022 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Mar 2, 2022 INTR
CANCELLED SECTION 71
Jul 2, 2021 C71T
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 10, 2020 TCCA
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Dec 16, 2019 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Jun 12, 2015 FINO
FINAL DISPOSITION NOTICE SENT TO IB
May 7, 2015 FICS
FINAL DISPOSITION PROCESSED
May 7, 2015 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 16, 2015 FICR
REGISTERED-PRINCIPAL REGISTER
Dec 16, 2014 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 30, 2014 NPUB
PUBLISHED FOR OPPOSITION
Sep 30, 2014 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 10, 2014 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 27, 2014 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 22, 2014 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 21, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 20, 2014 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Aug 20, 2014 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jul 3, 2014 GNFN
FINAL REFUSAL E-MAILED
Jul 3, 2014 GNFR
FINAL REFUSAL WRITTEN
Jul 3, 2014 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 10, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 10, 2014 CRFA
ASSIGNED TO LIE
Jun 5, 2014 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 23, 2014 TROA
REFUSAL PROCESSED BY IB
Apr 4, 2014 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 14, 2014 RFCS
REFUSAL PROCESSED BY MPU
Mar 14, 2014 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 14, 2014 RFCR
NON-FINAL ACTION WRITTEN
Mar 13, 2014 CNRT
APPLICATION FILING RECEIPT MAILED
Mar 11, 2014 MAFR
ASSIGNED TO EXAMINER
Mar 10, 2014 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 7, 2014 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 6, 2014 REPR